IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Two Sigma Securities LLC

Two Sigma Securities LLC decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 66.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,664 shares of the medical research company's stock after selling 3,275 shares during the quarter. Two Sigma Securities LLC's holdings in IQVIA were worth $327,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Synergy Asset Management LLC acquired a new position in shares of IQVIA during the fourth quarter valued at about $33,000. GKV Capital Management Co. Inc. acquired a new position in IQVIA during the 4th quarter valued at approximately $39,000. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA in the fourth quarter worth $44,000. Zions Bancorporation N.A. lifted its stake in shares of IQVIA by 55.2% during the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock worth $47,000 after buying an additional 85 shares during the period. Finally, Versant Capital Management Inc increased its position in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Price Performance

Shares of NYSE IQV opened at $150.38 on Monday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm has a fifty day moving average of $171.60 and a 200 day moving average of $193.55. The firm has a market cap of $26.51 billion, a PE ratio of 20.05, a PEG ratio of 1.99 and a beta of 1.46. IQVIA Holdings Inc. has a one year low of $135.97 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have commented on IQV. StockNews.com cut IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a research report on Friday. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price objective for the company from $260.00 to $160.00 in a research note on Friday. Truist Financial cut their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Finally, JPMorgan Chase & Co. decreased their target price on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating for the company in a research report on Tuesday, February 18th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, IQVIA has a consensus rating of "Moderate Buy" and an average price target of $237.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.